Terms: = Leukemia AND SEPT5, HCDCREL-1, 5413, ENSG00000184702, Q99719, PNUTL1, H5 AND Treatment
5 results:
1. Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis.
Stein EM; Bonifacio G; Latrémouille-Viau D; Shi S; Guérin A; Wu EQ; Sadek I; Cao X
J Med Econ; 2021; 24(1):234-243. PubMed ID: 33472483
[TBL] [Abstract] [Full Text] [Related]
2. Identification of target genes using gene expression profile of granulocytes from patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Mascarenhas Cdo C; Ferreira da Cunha A; Brugnerotto AF; Gambero S; de Almeida MH; Carazzolle MF; Pagnano KB; Traina F; Costa FF; de Souza CA
Leuk Lymphoma; 2014 Aug; 55(8):1861-9. PubMed ID: 24144310
[TBL] [Abstract] [Full Text] [Related]
3. MSF (MLL septin-like fusion), a fusion partner gene of MLL, in a therapy-related acute myeloid leukemia with a t(11;17)(q23;q25).
Osaka M; Rowley JD; Zeleznik-Le NJ
Proc Natl Acad Sci U S A; 1999 May; 96(11):6428-33. PubMed ID: 10339604
[TBL] [Abstract] [Full Text] [Related]
4. Tricyclic pyrone analogs: a new class of microtubule-disrupting anticancer drugs effective against murine leukemia cells in vitro.
Newell SW; Perchellet EM; Ladesich JB; Freeman JA; Chen Y; Liu L; Hua DH; Kraft SL; Basaraba RJ; Perchellet JP
Int J Oncol; 1998 Feb; 12(2):433-42. PubMed ID: 9458372
[TBL] [Abstract] [Full Text] [Related]
5. Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA.
Wickstrom EL; Bacon TA; Gonzalez A; Freeman DL; Lyman GH; Wickstrom E
Proc Natl Acad Sci U S A; 1988 Feb; 85(4):1028-32. PubMed ID: 3277186
[TBL] [Abstract] [Full Text] [Related]
